ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium

Rizzato,Cosmeri; Campa,Daniele; Pezzilli,Raffaele; Soucek,Pavel; Greenhalf,William; Capurso,Gabriele; Talar-Wojnarowska,Renata; Heller,Anette; Jamroziak,Krzysztof; Khaw,Kay-Tee; Key,Tim  J.; Bambi,Franco; Landi,Stefano; Mohelnikova-Duchonova,Beatrice; Vodickova,Ludmila; Büchler,Markus  W.; Bugert,Peter; Vodicka,Pavel; Neoptolemos,John  P.; Werner,Jens; Hoheisel,Jörg  D.; Bauer,Andrea  S.; Giese,Nathalia; Canzian,Federico

doi:10.3892/or.2013.2285

ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium

Authors:
- Cosmeri Rizzato
- Daniele Campa
- Raffaele Pezzilli
- Pavel Soucek
- William Greenhalf
- Gabriele Capurso
- Renata Talar-Wojnarowska
- Anette Heller
- Krzysztof Jamroziak
- Kay-Tee Khaw
- Tim J. Key
- Franco Bambi
- Stefano Landi
- Beatrice Mohelnikova-Duchonova
- Ludmila Vodickova
- Markus W. Büchler
- Peter Bugert
- Pavel Vodicka
- John P. Neoptolemos
- Jens Werner
- Jörg D. Hoheisel
- Andrea S. Bauer
- Nathalia Giese
- Federico Canzian
View Affiliations

Affiliations: Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany, Department of Digestive Diseases and Internal Medicine Sant'Orsola-Malpighi Hospital, Bologna, Italy, Department of Toxicogenomics, National Institute of Public Health, Prague, Czech Republic, Pancreas Biomedical Research Unit and the Liverpool Experimental Cancer Medicine Centre, National Institute for Health Research, Liverpool, UK, Digestive and Liver Disease Unit, ‘Sapienza' University of Rome, Rome, Italy, Department of Digestive Tract Diseases, Medical University, Lodz, Poland, Clinic for General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany, Department of Hematology, Medical University, Lodz, Poland, University of Cambridge School of Clinical Medicine, Cambridge, UK, Cancer Epidemiology Unit, University of Oxford, Oxford, UK, Blood Transfusion Service, Azienda Ospedaliero Universitaria Meyer, Florence, Italy, Department of Biology, University of Pisa, Pisa, Italy, Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Academy of Science of the Czech Republic and First Faculty of Medicine, Charles University in Prague, Czech Republic, Medical Faculty Mannheim, Institute of Transfusion Medicine and Immunology, Heidelberg University, German Red Cross Blood Service of Baden-Württemberg-Hessen, Mannheim, Germany
Published online on: February 12, 2013 https://doi.org/10.3892/or.2013.2285
Pages: 1637-1644

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is strong epidemiologic evidence indicating that common genetic variability could be implicated in pancreatic cancer risk and, to date, various loci have been proposed. In particular, there is increasing evidence of the involvement of ABO gene variability and pancreatic cancer risk. In a large multicentric study of 1,028 pancreatic ductal adenocarcinoma cases and 2,257 controls in the context of the PANcreatic Disease ReseArch (PANDoRA) consortium, we investigated the suggested association with increased risk for carriers of single nucleotide polymorphisms (SNPs) determining the A or B allele in comparison with the O allele, which encodes for a non-functional enzyme. Since glycosyltransferase activity, encoded by ABO, is higher for the A1 variant compared with the A2 variant, we investigated the hypothesis that A1 carriers were at an increased risk of pancreatic cancer. In our analysis, carriers of the A1 were indeed at greater risk of developing the disease. In addition, we investigated the possible influence that genetic variability at the ABO locus may have in pancreatic cancer survival, but we observed no effect in our population.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Anderson K, Mack T and Silverman D: Cancer of the pancreas. Oxford University Press; New York, NY: 2006
3	Hassan MM, Bondy ML, Wolff RA, et al: Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol. 102:2696–2707. 2007. View Article : Google Scholar : PubMed/NCBI
4	Jones S, Hruban RH, Kamiyama M, et al: Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 324:2172009. View Article : Google Scholar : PubMed/NCBI
5	Tischkowitz MD, Sabbaghian N, Hamel N, et al: Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology. 137:1183–1186. 2009. View Article : Google Scholar : PubMed/NCBI
6	Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al: Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 41:986–990. 2009. View Article : Google Scholar : PubMed/NCBI
7	Low SK, Kuchiba A, Zembutsu H, et al: Genome-wide association study of pancreatic cancer in Japanese population. PloS One. 5:e118242010. View Article : Google Scholar : PubMed/NCBI
8	Petersen GM, Amundadottir L, Fuchs CS, et al: A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 42:224–228. 2010. View Article : Google Scholar
9	Wu C, Miao X, Huang L, et al: Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat Genet. 44:62–66. 2011. View Article : Google Scholar : PubMed/NCBI
10	Wolpin BM, Chan AT, Hartge P, et al: ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 101:424–431. 2009. View Article : Google Scholar : PubMed/NCBI
11	Wolpin BM, Kraft P, Gross M, et al: Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res. 70:1015–1023. 2010. View Article : Google Scholar : PubMed/NCBI
12	Wolpin BM, Kraft P, Xu M, et al: Variant ABO blood group alleles, secretor status and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 19:3140–3149. 2010. View Article : Google Scholar : PubMed/NCBI
13	Moran AP, Gupta A and Joshi L: Sweet-talk: role of host glycosylation in bacterial pathogenesis of the gastrointestinal tract. Gut. 60:1412–1425. 2011. View Article : Google Scholar : PubMed/NCBI
14	Yip SP: Sequence variation at the human ABO locus. Ann Hum Genet. 66:1–27. 2002. View Article : Google Scholar : PubMed/NCBI
15	Ben Q, Wang K, Yuan Y and Li Z: Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Int J Cancer. 128:1179–1186. 2011. View Article : Google Scholar : PubMed/NCBI
16	Dandona M, Gao F, Linehan DC and Wang-Gillam A: Re: ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 102:135–137. 2010. View Article : Google Scholar : PubMed/NCBI
17	Engin H, Bilir C, Ustun H and Gokmen A: ABO blood group and risk of pancreatic cancer in a Turkish population in Western Blacksea region. Asian Pac J Cancer Prev. 13:131–133. 2012. View Article : Google Scholar : PubMed/NCBI
18	Campa D, Rizzato C, Capurso G, et al: Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. Dig Liver Dis. Nov 30–2012.(Epub ahead of print). View Article : Google Scholar
19	Rizzato C, Campa D, Giese N, et al: Pancreatic cancer susceptibility loci and their role in survival. PloS One. 6:e279212011. View Article : Google Scholar : PubMed/NCBI
20	Day N, Oakes S, Luben R, et al: EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 80(Suppl 1): 95–103. 1999.PubMed/NCBI
21	Davey GK, Spencer EA, Appleby PN, Allen NE, Knox KH and Key TJ: EPIC-Oxford: lifestyle characteristics and nutrient intakes in a cohort of 33 883 meat-eaters and 31 546 non meat-eaters in the UK. Public Health Nutr. 6:259–269. 2003. View Article : Google Scholar : PubMed/NCBI
22	Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
23	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
24	Hallouin F, Goupille C, le Cabellec M, Bara J and le Pendu J: Expression of A and H blood-group and of CD44 antigens during chemical rat colonic carcinogenesis. Glycoconj J. 14:801–808. 1997. View Article : Google Scholar : PubMed/NCBI
25	Hakomori S: Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta. 1473:247–266. 1999. View Article : Google Scholar
26	Hakomori S: Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol. 491:369–402. 2001. View Article : Google Scholar : PubMed/NCBI
27	Li D, Morris JS, Liu J, et al: Body mass index and risk, age of onset and survival in patients with pancreatic cancer. JAMA. 301:2553–2562. 2009. View Article : Google Scholar : PubMed/NCBI
28	Rahbari NN, Bork U, Hinz U, et al: AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer. 12:3192012. View Article : Google Scholar : PubMed/NCBI